These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Gao X; Fujii T; Ye BD; Chou JW; Sugimoto K; Cao Q; Kligys K; Murakoshi K; Teng D; Zhang Y; Nakase H J Gastroenterol Hepatol; 2024 Jan; 39(1):55-65. PubMed ID: 37788676 [TBL] [Abstract][Full Text] [Related]
10. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. Blauvelt A; Gordon KB; Lee P; Bagel J; Sofen H; Lockshin B; Soliman AM; Geng Z; Zhan T; Alperovich G; Stein Gold L J Dermatolog Treat; 2022 Jun; 33(4):2085-2093. PubMed ID: 33947295 [TBL] [Abstract][Full Text] [Related]
12. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Peyrin-Biroulet L; Ghosh S; Lee SD; Lee WJ; Griffith J; Wallace K; Berg S; Liao X; Panes J; Loftus EV; Louis E Aliment Pharmacol Ther; 2023 Mar; 57(5):496-508. PubMed ID: 36266762 [TBL] [Abstract][Full Text] [Related]
13. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763 [TBL] [Abstract][Full Text] [Related]
15. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease. Choi D; Sheridan H; Bhat S Ann Pharmacother; 2023 May; 57(5):579-584. PubMed ID: 36214282 [TBL] [Abstract][Full Text] [Related]
16. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related]
17. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Khanna R; Preiss JC; MacDonald JK; Timmer A Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580 [TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. Suleiman AA; Khatri A; Minocha M; Othman AA Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]